Novel combretastatin A-4 derivative XN0502 induces cell cycle arrest and apoptosis in A549 cells
- 30 March 2010
- journal article
- Published by Springer Science and Business Media LLC in Investigational New Drugs
- Vol. 28 (4), 493-501
- https://doi.org/10.1007/s10637-010-9424-4
Abstract
Combretastatin A-4 (CA-4) is a tubulin-binding compound currently in phase II trial as a tumor vascular-targeting agent. The present study evaluates the anti-tumor activities and establishes the mechanism of the action of 4-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-pyrazol-3-amine(XN0502), a novel synthesized CA-4 analogue, in an effort towards finding the favorable therapeutics of CA-4 derivatives. XN0502 is characterized by its more potent anti-proliferative activities against non-small cell lung cancer A549 cells (IC50: 1.8 ± 0.6 μM), than that on the normal human liver HL-7702 cells (IC50: 9.1 ± 0.4 μM). Of note, using tubulin polymerization assay, western blot and immuofluorescence analyses, XN0502 was showed to inhibit microtubule assembly at both molecular and cellular levels in A549 cells. Further studies indicated that XN0502 induced time- and dose-dependent G2/M arrest, accompanying with the reduction of CDC2/p34 expression and the downregulation of CDK7. The protein level alteration and the nuclear translocation of cyclinB1 were observed, denoting the M phase arrest in XN0502-treated cells. Moreover, XN0502 caused caspase-mediated apoptosis, as indicated by the cleavage of PARP, the reduction of procaspase-3 and procaspase-9, and the down-regulation of XIAP. Taken together, the current study demonstrates that the novel CA-4 analogue XN0502 is a promising anti-cancer agent with potent G2/M arrest- and apoptotic-inducing activities via targeting tubulin deserving further research and development, and helps provide data for exploiting new CA-4 analogues.Keywords
This publication has 32 references indexed in Scilit:
- The tubulin-depolymerising agent combretastatin-4 induces ectopic aster assembly and mitotic catastrophe in lung cancer cells H460Apoptosis, 2008
- MSFTZ, a Flavanone Derivative, Induces Human Hepatoma Cell Apoptosis via a Reactive Oxygen Species- and Caspase-Dependent Mitochondrial PathwayThe Journal of pharmacology and experimental therapeutics, 2008
- A Novel Oral Indoline-Sulfonamide Agent, N-[1-(4-Methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-Isonicotinamide (J30), Exhibits Potent Activity against Human Cancer Cells in Vitro and in Vivo through the Disruption of MicrotubuleThe Journal of pharmacology and experimental therapeutics, 2007
- Requirements for Cdk7 in the Assembly of Cdk1/Cyclin B and Activation of Cdk2 Revealed by Chemical Genetics in Human CellsMolecular Cell, 2007
- R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase IIMolecular Cancer Therapeutics, 2007
- A highly epothilone B–resistant A549 cell line with mutations in tubulin that confer drug dependenceMolecular Cancer Therapeutics, 2005
- The Tubulin-Binding Agent Combretastatin A-4-Phosphate Arrests Endothelial Cells in Mitosis and Induces Mitotic Cell DeathThe American Journal of Pathology, 2004
- Combretastatin A4 Phosphate Has Primary Antineoplastic Activity Against Human Anaplastic Thyroid Carcinoma Cell Lines and Xenograft TumorsThyroid®, 2002
- Microtubule Depolymerization in Rat Seminiferous Epithelium Is Associated with Diminished Tyrosination of α-Tubulin1Biology of Reproduction, 2001
- The spindle assembly checkpointCurrent Opinion in Cell Biology, 1996